Full Text View
Tabular View
No Study Results Posted
Related Studies
Tomotherapy Treatment for Mesothelioma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by Alberta Health Services.   Recruitment status was  Recruiting

First Received on May 2, 2007.   Last Updated on February 8, 2010   History of Changes
Sponsor: Alberta Health Services
Information provided by: Alberta Health Services
ClinicalTrials.gov Identifier: NCT00469196
  Purpose

Mesothelioma is an incurable cancer involving the lining of the lung. Patients usually suffer progressive symptoms of shortness of breath and chest pain, until they ultimately succumb to the disease. While a very small number of patients qualify for aggressive treatment with surgery, chemotherapy and radiation, and enjoy long-term survival, the vast majority of patients have incurable disease. The treatment options currently available, including chemotherapy and radiation treatment, are only modestly effective at alleviating symptoms and improving life expectancy. This trial explores the use of new radiation technology (tomotherapy), to treat mesothelioma more aggressively than has been possible before. Tomotherapy's ability to treat unusual shaped tumours, particularly when they are wrapped around sensitive normal tissues (the lung), enable higher doses of radiation to be used and this may improve its effectiveness. We will treat 17 patients with tomotherapy and assess the breathing, symptoms, and quality of life of the patients before and after treatment


Condition Intervention Phase
Mesothelioma
Procedure: Tomotherapy
Phase II

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Tomotherapy Treatment for Mesothelioma

Resource links provided by NLM:


Further study details as provided by Alberta Health Services:

Estimated Enrollment: 17
Study Start Date: October 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • histologic mesothelioma
  • refused/ineligible for surgery or chemotherapy
  • life expectancy >3 months

Exclusion Criteria:

  • contraindications to thoracic radiotherapy
  • unable to lie flat for duration of radiation therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00469196

Contacts
Contact: Rufus Scrimger, MD 780-432-8517 rufusscr@cancerboard.ab.ca

Locations
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T5N 2R8
Contact     780-432-8517     clinical_trials_cci@cancerboard.ab.ca    
Principal Investigator: Rufus Scrimger, MD            
Sponsors and Collaborators
Alberta Health Services
Investigators
Principal Investigator: Rufus Scrimger, MD Alberta Health Services
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00469196     History of Changes
Other Study ID Numbers: LU-11-0077
Study First Received: May 2, 2007
Last Updated: February 8, 2010
Health Authority: Canada: Health Canada

Keywords provided by Alberta Health Services:
mesothelioma
tomotherapy

Additional relevant MeSH terms:
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial

ClinicalTrials.gov processed this record on February 12, 2012